Conventional clinicopathologic prognostic factors in surgically resected nonsmall cell lung carcinoma: A comparison of prognostic factors for each pathologic TNM stage based on multivariate analyses

Cancer

Volumn 86, Issue 10, 1999, Pages 1976-1984

  Suzuki, Kenji ^a   Nagai, Kanji ^b   Yoshida, Junji ^b   Nishimura, Mitsuyo ^b   Takahashi, Kenro ^b   Yokose, Tomoyuki ^c   Nishiwaki, Yutaka ^b  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^c NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

Adjuvant therapy; Multivariate analysis; Pathologic TNM stage; Prognosis; Surgery

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; SQUAMOUS CELL CARCINOMA ANTIGEN;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 0033570968     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19991115)86:10<1976::AID-CNCR14>3.0.CO;2-I     Document Type: Article

References (62)

1. Asamura H, Nakajima T, Mukai K, Shimosato Y. Nuclear DNA content by cytofluorometry of Stage I adenocarcinoma of the lung in relation to postoperative recurrence. Chest 1989;96:312-8.
2. Asamura H, Nakajima T, Mukai K, Noguchi M, Shimosato Y. DNA cytofluorometric and nuclear morphometric analyses of lung adenocarcinoma. Cancer 1989;64:1657-64.
3. Slebos RJ, Kibbelaar RE, Dalesio O, Kooistra A, Stam J, Meijer CJ, et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 1990; 323:561-5.
4. Mitsudomi T, Steinberg SM, Oie HK, Mulshine JL, Phelps R, Viallet J, et al. ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. Cancer Res 1991;51:4999-5002.
5. Carey FA, Prasad US, Walker WS, Cameron EW, Lamb D, Bird CC. Prognostic significance of tumor deoxyribonucleic acid content in surgically resected small-cell carcinoma of lung. J Thorac Cardiovasc Surg 1992;103:1214-7.
6. Sugio K, Ishida T, Yokoyama H, Inoue T, Sugimachi K, Sasazuki T. ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis. Cancer Res 1992;52:2903-6.
7. Rosell R, Li S, Skacel Z, Mate JL, Maestre J, Canela M, et al. Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients. Oncogene 1993; 8:2407-12.
8. Mitsudomi T, Oyama T, Kusano T, Osaki T, Nakanishi R, Shirakusa T. Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer [see comments]. J Natl Cancer Inst 1993;85:2018-23.
9. Casson AG, McCuaig S, Craig I, Ayed A, Inculet R, Kerkvliet N, et al. Prognostic value and clinicopathologic correlation of p53 gene mutations and nuclear DNA content in human lung cancer: a prospective study. J Surg Oncol 1994;56:13-20.
10. Harpole DH Jr., Richards WG, Herndon JEN, Sugarbaker DJ. Angiogenesis and molecular biologic substaging in patients with Stage I non-small cell lung cancer. Ann Thorac Surg 1996;61:1470-6.
11. Adachi M, Taki T, Huang C, Higashiyama M, Doi O, Tsuji T, et al. Reduced integrin alpha3 expression as a factor of poor prognosis of patients with adenocarcinoma of the lung. J Clin Oncol 1998;16:1060-7.
12. Adachi M, Taki T, Ieki Y, Huang CL, Higashiyama M, Miyake M. Correlation of KAI1/CD82 gene expression with good prognosis in patients with non-small cell lung cancer. Cancer Res 1996;56:1751-5.
13. Adachi M, Taki T, Konishi T, Huang CI, Higashiyama M, Miyake M. Novel staging protocol for non-small-cell lung cancers according to MRP-1/CD9 and KAI1/CD82 gene expression. J Clin Oncol 1998;16:1397-406.
14. Higashiyama M, Doi O, Kodama K, Yokouchi H, Adachi M, Huang CL, et al. Immunohistochemically detected expression of motility-related protein-1 (MRP-1/CD9) in lung adenocarcinoma and its relation to prognosis. Int J Cancer 1997;74:205-11.
15. Higashiyama M, Kodama K, Yokouchi H, Takami K, Adachi M, Taki T, et al. KAI1/CD82 expression in nonsmall cell lung carcinoma is a novel, favorable prognostic factor: an immunohistochemical analysis. Cancer 1998;83:466-74.
16. Higashiyama M, Taki T, Ieki Y, Adachi M, Huang CL, Koh T, et al. Reduced motility related protein-1 (MRP-1/CD9) gene expression as a factor of poor prognosis in non-small cell lung cancer. Cancer Res 1995;55:6040-4.
17. Huang C, Taki T, Adachi M, Konishi T, Higashiyama M, Miyake M. Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer. Oncogene 1998;16:2469-77.
18. Kessler R, Gasser B, Massard G, Roeslin N, Meyer P, Wihlm JM, et al. Blood vessel invasion is a major prognostic factor in resected non-small cell lung cancer. Ann Thorac Surg 1996;62:1489-93.
19. Macchiarini P, Fontanini G, Hardin MJ, Chuanchieh H, Bigini D, Vignati S, et al. Blood vessel invasion by tumor cells predicts recurrence in completely resected T1 N0 M0 non-small-cell lung cancer. J Thorac Cardiovasc Surg 1993;106: 80-9.
20. McCaughan BC. Primary lung cancer invading the chest wall. Chest Surg Clin N Am 1994;4:17-28.
21. Ichinose Y, Yano T, Asoh H, Yokoyama H, Yoshino I, Katsuda Y. Prognostic factors obtained by a pathologic examination in completely resected non-small-cell lung cancer. An analysis in each pathologic stage. J Thorac Cardiovasc Surg 1995; 110:601-5.
22. Hilsenbeck SG, Raub WA Jr., Sridhar KS. Prognostic factors in lung cancer based on multivariate analysis. Am J Clin Oncol 1993;16:301-9.
23. Harpole DH Jr., Herndon JEN, Young WG Jr., Wolfe WG, Sabiston DC Jr. Stage I nonsmall cell lung cancer. A multivariate analysis of treatment methods and patterns of recurrence. Cancer 1995;76:787-96.
24. Cybulsky IJ, Lanza LA, Ryan MB, Putnam JB Jr., McMurtrey MM, Roth JA. Prognostic significance of computed tomography in resected N2 lung cancer [see comments]. Ann Thorac Surg 1992;54:533-7.
25. Icard P, Regnard JF, Essomba A, Panebianco V, Magdeleinat P, Levasseur P. Preoperative carcinoembryonic antigen level as a prognostic indicator in resected primary lung cancer. Ann Thorac Surg 1994;58:811-4.
26. Vansteenkiste JF, De Leyn PR, Deneffe GJ, Stalpaert G, Nackaerts KL, Lerut TE, et al. Survival and prognostic factors in resected N2 non-small cell lung cancer: a study of 140 cases. Leuven Lung Cancer Group. Ann Thorac Surg 1997;63:1441-50.
27. Kurokawa T, Matsuno Y, Noguchi M, Mizuno S, Shimosato Y. Surgically curable "early" adenocarcinoma in the periphery of the lung [see comments]. Am J Surg Pathol 1994;18: 431-8.
28. Yano T, Yokoyama H, Inoue T, Asoh H, Tayama K, Ichinose Y. Surgical results and prognostic factors of pathologic N1 disease in non-small-cell carcinoma of the lung. Significance of Nl level: lobar or hilar nodes [see comments]. J Thorac Cardiovasc Surg 1994;107:1398-402.
29. Yoshino I, Yokoyama H, Yano T, Ueda T, Takai E, Mizutani K, et al. Skip metastasis to the mediastinal lymph nodes in non-small cell lung cancer. Ann Thorac Surg 1996;62: 1021-5.
30. van Velzen E, Snijder RJ, Brutel de la Riviere A, Elbers HR, van den Bosch JM. Lymph node type as a prognostic factor for survival in T2 N1 M0 non-small cell lung carcinoma. Ann Thorac Surg 1997;63:1436-40.
31. van Klaveren RJ, Festen J, Otten HJ, Cox AL, de Graaf R, Lacquet LK. Prognosis of unsuspected but completely resectable N2 non-small cell lung cancer. Ann Thorac Surg 1993;56:300-4.
32. Carles J, Rosell R, Ariza A, Pellicer I, Sanchez JJ, Fernandez-Vasalo G, et al. Neuroendocrine differentiation as a prognostic factor in non-small cell lung cancer. Lung Cancer 1993;10:209-19.
33. World Health Organization. Histological typing of lung tumors. 2nd ed. Geneva: World Health Organization, 1981.
34. Sobin LH, Wittekind C. International Union Against Cancer: TNM classification of malignant tumours. 5th ed. New York: Wiley-Liss, Inc., 1997.
35. Shimosato Y, Suzuki A, Hashimoto T, Nishiwaki Y, Kodama T, Yoneyama T, et al. Prognostic implications of fibrotic focus (scar) in small peripheral lung cancers. Am J Surg Pathol 1980;4:365-73.
36. Kaplan EL, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958;53:457-81.
37. Cox D. The analysis of binary data. London: Methuen, 1970.
38. Ichinose Y, Hara N, Ohta M, Yano T, Maeda K, Asoh H, et al. Is T factor of the TNM staging system a predominant prognostic factor in pathologic Stage I non-small-cell lung cancer? A multivariate prognostic factor analysis of 151 patients. J Thorac Cardiovasc Surg 1993;106:90-4.
39. Snijder RJ, Brutel de la Riviere A, Elbers HJ, van den Bosch JM. Survival in resected Stage I lung cancer with residual tumor at the bronchial resection margin. Ann Thorac Surg 1998;65:212-6.
40. Liewald F, Hatz RA, Dienemann H, Sunder-Plassmann L. Importance of microscopic residual disease at the bronchial margin after resection for non-small-cell carcinoma of the lung. J Thorac Cardiovasc Surg 1992;104:408-12.
41. Lacasse Y, Bucher HC, Wong E, Griffith L, Walter S, Ginsberg RJ, et al. "Incomplete resection" in non-small cell lung cancer: need for a new definition. Canadian Lung Oncology Group. Ann Thorac Surg 1998;65:220-6.
42. Maruyama R, Sugio K, Mitsudomi T, Saitoh G, Ishida T, Sugimachi K. Relationship between early recurrence and micrometastases in the lymph nodes of patients with Stage I non-small-cell lung cancer. J Thorac Cardiovasc Surg 1997; 114:535-43.
43. Dobashi K, Sugio K, Osaki T, Oka T, Yasumoto K. Micrometastatic P53-positive cells in the lymph nodes of non-small-cell lung cancer: prognostic significance. J Thorac Cardiovasc Surg 1997;114:339-46.
44. Martini N, Beattie EJ Jr. Results of surgical treatment in Stage I lung cancer. J Thorac Cardiovasc Surg 1977;74:499-505.
45. The Lung Cancer Study Group. Postoperative T1 N0 non-small cell lung cancer. Squamous versus nonsquamous recurrences. J Thorac Cardiovasc Surg 1987;94:349-54.
46. Noguchi M, Morikawa A, Kawasaki M, Matsuno Y, Yamada T, Hirohashi S, et al. Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer 1995;75: 2844-52.
47. Kaneko M, Eguchi K, Ohmatsu H, Kakinuma R, Naruke T, Suemasu K, et al. Peripheral lung cancer: screening and detection with low-dose spiral CT versus radiography. Radiology 1996;201:798-802.
48. Rubins JB, Dunitz J, Rubins HB, Maddaus MA, Niewoehner DE. Serum carcinoembryonic antigen as an adjunct to preoperative staging of lung cancer. J Thorac Cardiovasc Surg 1998;116:412-6.
49. Suzuki K, Nagai K, Yoshida J, Nishimura M, Takahashi K, Nishiwaki Y. Clinical predictors of N2 disease in the setting of a negative computed tomographic scan in patients with lung cancer. J Thorac Cardiovasc Surg 1999;117:593-8.
50. Hinds MW, Yang HY, Stemmermann G, Lee J, Kolonel LN. Smoking history and lung cancer survival in women. J Natl Cancer Inst 1982;68:395-9.
51. Horwitz RI, Smaldone LF, Viscoli CM. An ecogenetic hypothesis for lung cancer in women [see comments]. Arch Intern Med 1988;148:2609-12.
52. Sobue T, Suzuki T, Horai T, Matsuda M, Fujimoto I. Relationship between cigarette smoking and histologic type of lung cancer, with special reference to sex difference. Jpn J Clin Oncol 1988;18:3-13.
53. Sekine I, Nagai K, Tsugane S, Yokose T, Kodama T, Nishiwaki Y, et al. Association between smoking and tumor progression in Japanese women with adenocarcinoma of the lung. Jpn J Cancer Res 1999;90:129-35.
54. Sekine I, Nishiwaki Y, Yokose T, Nagai K, Suzuki K, Kodama T. Young lung cancer patients in Japan: different characteristics between the sexes. Ann Thorac Surg 1999;67:1451-5.
55. Martini N, Burt ME, Bains MS, McCormack PM, Rusch VW, Ginsberg RJ. Survival after resection of Stage II non-small cell lung cancer [discussion 6]. Ann Thorac Surg 1992;54: 460-5.
56. Martini N, Bains MS, Burt ME, Zakowski MF, McCormack P, Rusch VW, et al. Incidence of local recurrence and second primary tumors in resected Stage I lung cancer. J Thorac Cardiovasc Surg 1995;109:120-9.
57. Miller DL, McManus KG, Allen MS, Ilstrup DM, Deschamps C, Trastek VF, et al. Results of surgical resection in patients with N2 non-small cell lung cancer [discussion 100-1]. Ann Thorac Surg 1994;57:1095-100.
58. Goldstraw P, Mannam GC, Kaplan DK, Michail P. Surgical management of non-small-cell lung cancer with ipsilateral mediastinal node metastasis (N2 disease) [discussion-8]. J Thorac Cardiovasc Surg 1994;107:19-27.
59. Pearson FG, DeLarue NC, lives R, Todd TR, Cooper JD. Significance of positive superior mediastinal nodes identified at mediastinoscopy in patients with resectable cancer of the lung. J Thorac Cardiovasc Surg 1982;83:1-11.
60. Shields TW. The significance of ipsilateral mediastinal lymph node metastasis (N2 disease) in non-small cell carcinoma of the lung. A commentary. J Thorac Cardiovasc Surg 1990;99:48-53.
61. Harpole DH Jr., Healey EA, DeCamp MM Jr., Mentzer SJ, Strauss GM, Sugarbaker DJ. Chest wall invasive non-small cell lung cancer: patterns of failure and implications for a revised staging system. Ann Surg Oncol 1996;3:261-9.
62. Martini N, Flehinger BJ. The role of surgery in N2 lung cancer. Surg Clin North Am 1987;67:1037-49.